A claims-based analysis published in Clinical Gastroenterology and Hepatology found that overall cancer incidence was low and comparable across four major classes of advanced IBD therapies. The retrospective study included 15,687 adults with IBD who initiated TNF antagonists, vedolizumab, anti-interleukin therapies or JAK inhibitors between…
A Maricopa County jury sided with a gastroenterologist accused of failing to diagnose a fatal bowel obstruction, declining a $26.6…
Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting…
Olympus’ $1M+ equipment grant to ASGE isn’t just philanthropy—it’s a strategic investment in shaping the next generation of endoscopists and,…
Walgreens is taking colorectal cancer screening out of the clinic and into retail—partnering with Exact Sciences to offer Cologuard access…
DDW 2026
Several studies presented at DDW 2026 highlighted emerging approaches that could reshape…
A structured triage system for interventional GI referrals changed the originally requested…
Thought Leadership
In a wide-ranging interview, Byron L. Cryer, MD, president of the American…
How New Capabilities Enter Mainstream GI By Dr. Charles Accurso and Praveen…
The hidden cost of administrative work extends far beyond unpaid overtime, according…